TY - JOUR
T1 - Multiplex pcr to detect pampc β-lactamases among enterobacteriaceae at a tertiary care laboratory in Mumbai, India
AU - Kazi, Mubin
AU - Ajbani, Kanchan
AU - Tornheim, Jeffrey A.
AU - Shetty, Anjali
AU - Rodrigues, Camilla
N1 - Funding Information:
This study was funded by the National Health and Education Society, P. D. Hinduja National Hospital and Medical Research Centre. Dr Jeffrey A. Tornheim (J. A. T.) was supported by a Johns Hopkins University Clinician Scientist Award, the UJMT Fogarty Global Health Fellows Program (R25TW009340), NIH/NIAID (R21AI122922), the Ujala Foundation, the Gilead Foundation and the Wyncote Foundation.
Publisher Copyright:
© 2019 The Authors.
PY - 2019/2
Y1 - 2019/2
N2 - Drug-resistance due to AmpC β-lactamases represents a growing problem worldwide. In this study, a previously collected sample of 108 cefoxitin-resistant clinical isolates was assessed for AmpC b-lactamase production through routine phenotypic testing and double-disc cefoxitin/cloxcallin (DD-CC), cefoxitin/phenylboronic acid (CDT-PBA) and AmpC disc tests. The same isolates were characterized by a novel multiplex polymerase chain reaction molecular assay to detect the presence of bla ACT , bla DHA , bla CIT , bla FOX , bla MIR and bla MOX . By phenotypic analysis, 56%, 55% and 48 % were detected as being AmpC β-lactamase producers by the CDT-PBA, DD-CC and AmpC disc tests, respectively. By molecular analysis, 57 % were determined to be AmpC β-lactamase producers, including 34 % bla FOX , 8 % bla CIT and 1.6 % bla DHA as mono-AmpC producers. The production of multiple AmpC molecular types was common, including 30 % with both bla CIT+FOX and 1.6 % each of bla CIT+DHA , bla ACT+MIR , bla ACT+FOX , bla ACT+DHA and bla MIR+FOX . Molecular characterization of AmpC would help detect the prevalence of AmpC β-lactamase producers, facilitate proper patient management and implement infection control practices.
AB - Drug-resistance due to AmpC β-lactamases represents a growing problem worldwide. In this study, a previously collected sample of 108 cefoxitin-resistant clinical isolates was assessed for AmpC b-lactamase production through routine phenotypic testing and double-disc cefoxitin/cloxcallin (DD-CC), cefoxitin/phenylboronic acid (CDT-PBA) and AmpC disc tests. The same isolates were characterized by a novel multiplex polymerase chain reaction molecular assay to detect the presence of bla ACT , bla DHA , bla CIT , bla FOX , bla MIR and bla MOX . By phenotypic analysis, 56%, 55% and 48 % were detected as being AmpC β-lactamase producers by the CDT-PBA, DD-CC and AmpC disc tests, respectively. By molecular analysis, 57 % were determined to be AmpC β-lactamase producers, including 34 % bla FOX , 8 % bla CIT and 1.6 % bla DHA as mono-AmpC producers. The production of multiple AmpC molecular types was common, including 30 % with both bla CIT+FOX and 1.6 % each of bla CIT+DHA , bla ACT+MIR , bla ACT+FOX , bla ACT+DHA and bla MIR+FOX . Molecular characterization of AmpC would help detect the prevalence of AmpC β-lactamase producers, facilitate proper patient management and implement infection control practices.
KW - AmpC disk test
KW - AmpC β-lactamases
KW - Cefoxitin-resistance
KW - Cefoxtin-Cloxcallin
KW - Molecular characterization
UR - http://www.scopus.com/inward/record.url?scp=85061153880&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85061153880&partnerID=8YFLogxK
U2 - 10.1099/mic.0.000748
DO - 10.1099/mic.0.000748
M3 - Article
C2 - 30543509
AN - SCOPUS:85061153880
VL - 165
SP - 246
EP - 250
JO - Journal of General Microbiology
JF - Journal of General Microbiology
SN - 1350-0872
IS - 2
M1 - 000748
ER -